We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


New 384-well Assay from Affymetrix

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

The easy-to-use, high-sensitivity assay measures gene expression with minimal sample preparation, using branched DNA for signal amplification. A key feature of the assay is that it does not require RNA or DNA purification, reverse transcription, or PCR amplification, so biases and sample losses resulting from these preparation steps are eliminated. This robust assay, also available in a 96-well format, can directly detect gene expression changes as small as 10 percent. The Z-factors of the QuantiGene Singleplex HT Assay are consistently higher than those of other assay types such as qPCR. 

Affymetrix QuantiGene Singleplex HT Image.jpg

Ideal applications for QuantiGene Singleplex HT Assay include compound screening in drug discovery, biomarker validation, and siRNA knockdown studies. The assay accommodates a range of sample types, including heavily degraded and cross-linked RNA in FFPE samples and RNA in blood. 

“This new, automation-friendly 384-well assay format fits with current workflows because cells are most commonly cultured in 384-well plates for high-throughput screening,” commented Brian McLucas, product manager for Affymetrix. “Furthermore, the limiting step with qPCR is RNA purification, which is completely avoided with QuantiGene assays. Gene expression-based high-throughput screening of hundreds of thousands of compounds can be carried out in just weeks.”